Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-08-12), Sansure Biotech's share price is ¥15.36.
Sansure Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.26. Therefore, Sansure Biotech's PE Ratio for today is 59.31.
During the past 9 years, Sansure Biotech's highest PE Ratio was 70.69. The lowest was 5.98. And the median was 19.04.
Sansure Biotech's EPS (Diluted) for the
three
months ended in Mar. 2026 was ¥0.08.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.26.
During the past 12 months, Sansure Biotech's average EPS without NRIGrowth Rate was -55.50% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was -54.80% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -50.00% per year.
During the past 9 years, Sansure Biotech's highest 3-Year average EPS without NRI Growth Rate was 242.40% per year. The lowest was -70.50% per year. And the median was -54.70% per year.
Sansure Biotech's EPS (Basic) for the
three
months ended in Mar. 2026 was ¥0.08.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.26.
Sansure Biotech (SHSE:688289) PE Ratio Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.
Sansure Biotech PE Ratio Related Terms
Sansure Biotech PE Ratio Historical Data
* Premium members only.
The historical data trend for Sansure Biotech's PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688289 vs ISRG, BDX, MDLN: PE Ratio Comparison
For the Medical Instruments & Supplies subindustry, Sansure Biotech's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sansure Biotech PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sansure Biotech's PE Ratio distribution charts can be found below:
* The bar in red indicates where Sansure Biotech's PE Ratio falls into.
The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Sansure Biotech's Share Price of today is ¥15.36. Sansure Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.26.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Sansure Biotech (SHSE:688289) has a PE Ratio of 59.31 as of Aug. 12, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Sansure Biotech and its competitors. This is 212% above median its historical median of 19.04. Over the past decade, Sansure Biotech's PE Ratio has ranged from 5.98 to 70.69.
Is Sansure Biotech's PE Ratio too high?
Sansure Biotech's current PE Ratio of 59.31 is 212% above median its 10-year median of 19.04. Over the past 10 years, this metric has ranged from a low of 5.98 to a high of 70.69. Overall, Sansure Biotech has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sansure Biotech's PE Ratio compare to ISRG and BDX?
Sansure Biotech's PE Ratio of 59.31 can be compared against companies in the Medical Devices & Instruments industry. Historically, Sansure Biotech's own PE Ratio has ranged from 5.98 to 70.69 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Medical Devices & Instruments company?
A good PE Ratio depends on the Medical Devices & Instruments industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Sansure Biotech and its competitors. Sansure Biotech's current PE Ratio is 59.31, which is 212% above median its own 10-year median of 19.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sansure Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sansure Biotech (SHSE:688289) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥17.92, compared to a current price of ¥15.36 — trading 14.3% below its estimated fair value. The current PE Ratio is 59.31, which is 212% above median its 10-year median of 19.04. Sansure Biotech's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For Sansure Biotech (SHSE:688289), the current PE Ratio is 59.31 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sansure Biotech (SHSE:688289) Overvalued in 2026?
Based on GuruFocus' analysis, Sansure Biotech stock appears to be undervalued.
The current stock price of ¥15.36 is trading 14.3% below its estimated GF Value™ of ¥17.92.
GuruFocus considers Sansure Biotech to be Modestly Undervalued.
Key valuation signals for SHSE:688289:
PE Ratio: 59.31 (212% above median its 10-year median of 19.04)
GF Value™: ¥17.92 vs. price of ¥15.36 (14.3% below fair value)
No single metric tells the full story. See the SHSE:688289 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688289 has been successfully added to your 
